YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Development of Regulation System for Off-Label Drug Use

의약품 허가외사용 관리 체계 발전 방안

  • Received : 2014.01.29
  • Accepted : 2014.04.22
  • Published : 2014.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study aimed to develop a regulation system for off-label drug use to secure the safe use of marketed drugs. We searched governmental documents for national and global regulating systems of off-label drug uses and a body of academic literature to explore current regulating trends. We included European Union, United Kingdom, United States of America, Australia and Japan, and critically reviewed the regulation of off-label drug use in four issues, which were a regulatory structure, safety control before and after off-label use, and information management. The findings of the present investigation called for several measures in off-label drug uses: enhancing prescribers' self-regulation, providing up-to-date information to prescribers for evidence-based practice and to patients for their informed consent, making evidence with scientific rigor, building an official registering process for off-label use in good quality and extending the role of pharmaceutical industry in pharmacovigilance. At last, we proposed a new system so as to regulate and evaluate off-label drug uses both at national and institutional level. In the new system, we suggested a clear-cut definition for clinical evidence that applicants would submit. We newly introduced an official 'Off-Label Drug Use Report' to evaluate the safety and clinical efficacy of a given off-label drug use. In addition, we developed an algorism of the regulation of off-label drug use within an institution to help set up the culture of evidence-based practices in off-label drug uses.

Keywords

References

  1. 중앙사회보험의료협의회 : 의료보험에 있어서 혁신적인 의료기술의 취급에 관한 방법에 대해 ( 療保における革新的な療技 術の取扱いにする考え方について) (2010).
  2. Kim, J. M. : Off-label use. Korean J. Insur. Med. 7, 157 (2012).
  3. Radley, D. C., Finkelstein, S. N. and Stafford, R. S. : Off-label prescribing among office-based physicians. Arch. Intern. Med. 166, 1021 (2006). https://doi.org/10.1001/archinte.166.9.1021
  4. Lindell-Osuagwu, L., Korhonen, M. J., Saano, S., Helin- Tanninen, M., Naaranlahti, T. and Kokki, H. : Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J. Clin. Pharm. Ther. 34, 277 (2009). https://doi.org/10.1111/j.1365-2710.2008.01005.x
  5. Turner, S. : Unregistered and off-label drug use in paediatric inpatients. Aust. J. Hosp. Pharm. 29, 265 (1999). https://doi.org/10.1002/jppr1999295265
  6. DTB : Prescribing unlicensed drugs or using drugs for unlicensed indications. Drug Ther. Bull. 30, 97 (1992).
  7. Chen, D. T., Wynia, M. K., Moloney, R. M. and Alexander, G. C. : U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 18, 1094 (2009). https://doi.org/10.1002/pds.1825
  8. Shin, J.-Y., Jung, S.-Y. and Park, B.-J. : Off-label drug use and its implications for evidence-based decision making. J. Pharmacoepidemiol Risk Manage. 3, 1 (2010).
  9. Ufer, M., Kimland, E. and Bergman, U. : Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 13, 147 (2004). https://doi.org/10.1002/pds.858
  10. Cuzzolin, L., Atzei, A. and Fanos, V. : Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert. Opin Drug Saf. 5, 703 (2006). https://doi.org/10.1517/14740338.5.5.703
  11. 어윤호 : MBC '시사매거진 2580', 미 허가약품 '싸이토텍' 고발. 메디컬투데이 (2009). Available from http://www.mdtoday.co.kr/ mdtoday/index.html?no=102698&cate=&sub=&key= &word=&page=1 (accessed 2014. Apr. 7).
  12. 이탁순 : '테르부탈린' 제제 임부 대상 오프라벨 사용 금지. 데일리팜 (2011). Available from http://www.dailypharm.com/ Users/News/NewsView.html?ID=137164 (accessed 2014. Apr. 7).
  13. Stafford, R. S. : Regulating Off-Label Drug Use--Rethinking the Role of the FDA. N. Engl. J. Med. 358, 1427 (2008). https://doi.org/10.1056/NEJMp0802107
  14. 이탁순 : 오프라벨 효과 평가, 임의비급여 정리되나. 데일리팜 (2010). Available from http://www.dailypharm.com/Users/ News/NewsView.html?ID=122812 (accessed 2014. Apr. 7).
  15. 이탁순 : 오프라벨 사용지침 필요, 레이블 수시 교체해야. 데일리팜 (2011). Available from http://www.dailypharm.com/Users/ News/NewsView.html?ID=140518 (accessed 2014. Apr. 7).
  16. 이탁순 : 오프라벨 심사 '따로따로' 환자진료 혼란 초래. 데일리팜 (2011). Available from http://www.dailypharm.com/Users/ News/NewsView.html?ID=146430 (accessed 2014. Apr. 7).
  17. Korea Food & Drug Administration : 2010 list of FDA regulatory reforms. Seoul, Korea Food & Drug Administration (2010).
  18. Garattini, S. and Bertele', V. : The role of the EMEA in regulating pharmaceutical products. In: Mossialos E, Mrazek M, Walley T, eds., Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Open University Press. Maidenhead. p. 80 (2004).
  19. MHRA : Drug safety update. (2011). Available from http:// www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON087990 (accessed 2012. Jul. 30).
  20. General Medical Council : Good practice in prescribing medicines. General Medical Council (2008).
  21. NICE : Evidence summaries: unlicensed/off-label medicines. (2013). Available from http://www.nice.org.uk/mpc/ evidencesummariesunlicensedofflabelmedicines/ (2014. Jan. 27).
  22. Working group on paediatric medicines: Evaluation of the efficacy and safety of buspirone in children and adolescents aged <18 years. London, Medicines and Healthcare products Regulatory Agency (2004).
  23. European Commission : Guidelines on Pharmacovigilance for Medicinal Products for Human Use (2008).
  24. EMEA : Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. London, European Medicines Agency, Committee for Medicinal Products for Human Use (2006).
  25. EURORDIS : EURORDIS response to the European Commission Public Consultation "Legal proposal on information to patients" (2008).
  26. Hampton, T. : Experts weigh in on promotion, prescription of off-label drugs. JAMA. 297, 683 (2007).
  27. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation Research, Center for Veterinary MedicineandCenter for Devices and Radiological Health : Responding to unsolicited requests for off-label information about prescription drugs and medical devices (2011).
  28. Blue Cross Blue Shield : Off-Label Use of U.S. FDA Approved Drugs. (2013). Available from https://www.bcbsmt.com/ MedReview/Policies/OffLabelDrugUse/v102.aspx (accessed 2014. Jan. 29).
  29. AmeriHealth : Experimental/Investigational/Off-label drug use. Pharmacy Policy Bulletin. (2013). Available from http:// www.amerihealth.com/pdfs/providers/pharmacy_information/ pharmacy_policies/experimental_drug_use.pdf (accessed 2014. Jan. 29).
  30. Abernethy, A. P., Raman, G., Balk, E. M., Hammond, J. M., Orlando, L. A., Wheeler, J. L., Lau, J. and McCrory, D. C. : Systematic Review: Reliability of Compendia Methods for Off- Label Oncology Indications. Ann. Intern. Med. 150, 336 (2009). https://doi.org/10.7326/0003-4819-150-5-200903030-00107
  31. US FDA : FDA Adverse Event Reporting System (FAERS) Website (2012). Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm (accessed 2014. Jan. 9).
  32. Weiss, B. D., Coyne, C., Michielutte, R., Davis, T. C., Meade, C. D., Doak, L. G., Cecilia, C. D., Brown, P., Askov, E., Mettger, W., Songer, T., Friedell, G. H. and Smith, T. : Communicating with patients who have limited literacy skills: Report of the National Work Group on Literacy and Health. J. Fam Pract. 46, 168 (1998).
  33. Coulter, A., Parsons, S. and Askham, J. : Where are the patients in decision-making about their own care? WHO European Ministerial Conference on Health Systems. Tallinn, Estonia (2008).
  34. Consumer Reports : "Off-Label" drug use. Shopper's guide to prescription durgs - number 6. (2007) Available from http:// www.consumerreports.org/health/resources/pdf/best-buydrugs/ money-saving-guides/english/Off-Label-FINAL.pdf (accessed 2012. Mar. 22).
  35. 가가와대학의학부 부속병원 : 적응외 사용(適外使用). (2008). Available from http://www.kms.ac.jp/-yakuzaib/CTMcenter/ outside/index.html (accessed 2012. Aug. 20).
  36. Palate, V. : The Impact of Off-Label, Compassionate and Unlicensed Use on Health Care Laws in preselected Countries. Bonn, Drug Regulatory Affairs, Rheinishe Friedrich-Wilhelms-University (2009).
  37. 보건후생노동성 : 의약품의 적응외사용에 관한 보험진료상의 취급에 대해 ( 品の適外使用に係る保診療上の取扱いについて ) (2010).
  38. Lee, S., Lee, I.-H., Lee, Y. S., Kye, S. and Seo, M. : Development of regulation system for evaluation of off-label drug use. College of Pharmacy, Ajou University, Korea Food & Drug Administration (2012).
  39. 보건후생노동성 : 미승인약, 적응외약의 해소를 위한 검토에 대해 (未承認.適外解消に向けての討について) (2011).
  40. 중앙제약단체연합회 : 약가제도개혁에 관현 의견( 制度改革に する意見) (2011).
  41. 중앙사회보험의료협의회 : 공지신청된 적응외약의 보험적용에 관해 (公知申￦請とされた適外の保適用について) (2010).
  42. Nakano, T. : Pharmaceutical laws and Regulations. Pharmaceutical administration and regulations in Japan, Japan Pharmaceutical Manufacturers Association (2010).
  43. 보건후생노동성 : 제약기업으로부터 의료기관에의 적응외사용 정보제공의 정리(平成21年度厚生勞動科學- 究費補助金 厚生勞動 科學特別硏究事業 分硏究報告書 3. 製藥企業から醫療機關への 適應外使用情報提供の整理). 후생노동과학특별연구사업 분담연구고서 (2009).
  44. Faculty of Pain Medicine ANZCA (FPM) : Use of "off label" or drugs beyond license in pain medicine. (2007). Available from http://www.fpm.anzca.edu.au/resources/educationaldocuments/ documents/use-of-off-label-drugs-or-beyondlicence/ (accessed 2012. Aug. 18).
  45. Gazarian, M., Kelly, M., McPhee, J. R., Graudins, L. V., Ward, R. L. and Campbell, T. J. : Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med. J. Aust. 185, 544 (2006).
  46. NSW Department of Health : Off label use of registered medicines and use of medicines under the personal importation scheme in NSW public hospitals. (2003). Available from http://www.ciap.health.nsw.gov.au/nswtag/publications/ otherdocs/off_label_useregistered_medicines (accessed 2012. Aug. 2).
  47. Lee, S. M. : Evidence-based healthcare: Seeking for the broken virtuous circle. J. Korean Med. Association. 52, 532 (2009). https://doi.org/10.5124/jkma.2009.52.6.532